NCT05592665Active, not recruiting
PRO-VISION: Patient Reported Outcomes-Based Monitoring of VEGF-Inhibitor Side Effects in ONcology
Source: ClinicalTrials.gov · Last updated 12 May 2026
Brief summary (registry, in English)
The purpose of this study is to investigate how collecting information about treatment-related side effects directly from patients can help manage the side effects associated with certain oral chemotherapies. This study is specifically investigating this approach in patients taking oral vascular endothelial growth factor receptor (VEGFR) tyrosine kinase inhibitors (TKIs) for metastatic renal cell carcinoma (mRCC). Participants in this study will receive a survey via email or telephone once a week while receiving treatment with a VEGFR TKI. The survey will ask about symptoms such as nausea or fatigue and overall quality of life. This survey should take no more than 15 minutes to complete. The survey will be sent directly to the oncology care team. Participants will receive a follow-up phone call or message from the team when participants have new or worsening symptoms. The participants will continue to receive surveys for as long as they are receiving a VEGF TKI treatment.
- Status (registry)
- Active, not recruiting
- Study type
- Interventional
- Enrollment
- 42 (actual)
- First submitted
- 20 Sept 2022
- Start date
- 18 Mar 2022
- Primary completion date
- 16 Jan 2027
- Lead sponsor
- UNC Lineberger Comprehensive Cancer Center
- Diseases
- Kidney cancer
- NCT number
- NCT05592665
What you commit to
- Study type: Interventional
- Participants enrolled: 42
- From 18 Mar 2022 to the primary completion date, 16 Jan 2027
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other
- All subjects meeting any of the exclusion criteria at baseline will be excluded from study participation.
- Inability for any reason to complete PRO surveys
Who the study is looking for
- Adult patients aged 18 years or older
- Histologically confirmed renal cell carcinoma requiring treatment with VEGF TKI.
- Patients may be receiving other concurrent cancer-directed therapy such as immune checkpoint inhibitors.
- English or Spanish speaking
- Ability to complete PRO surveys (i.e. ability to read/write or access to telephone or internet)
- Willing and able to meet all study requirements
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Lineberger Comprehensive Cancer Center Coordinator of this site? Confirm its status | Chapel Hill | United States | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.